Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.63 |
| ▸ | CES2 | O00748 | 1/20 | 0.63 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | USP19 | O94966 | 1/20 | 0.32 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428184 | 0.89 | FAAH (0.78) | FAAHCES2NPC1RAB9AUSP19 | |
| SCHEMBL426101 | 0.89 | FAAH (0.81) | FAAHCES2TGFBR1HSD11B1PDE4B | |
| SCHEMBL427868 | 0.86 | FAAH (0.59) | FAAHCES2TGFBR1HSD11B1PDE4B | |
| SCHEMBL14950261 | 0.85 | FAAH (0.53) | FAAHCES2TGFBR1HSD11B1NPC1 | |
| SCHEMBL427732 | 0.85 | FAAH (0.53) | FAAHCES2TGFBR1HSD11B1NPC1 | |
| SCHEMBL426220 | 0.85 | FAAH (0.53) | FAAHCES2TGFBR1HSD11B1MCHR1 | |
| SCHEMBL427871 | 0.84 | FAAH (0.52) | FAAHCES2TGFBR1PDE4BNPC1 | |
| SCHEMBL427361 | 0.84 | FAAH (0.52) | FAAHCES2TGFBR1PDE4BCYP46A1 | |
| SCHEMBL14937605 | 0.83 | FAAH (0.51) | FAAHCES2TGFBR1NPC1RAB9A | |
| SCHEMBL426156 | 0.82 | FAAH (0.50) | FAAHCES2NPC1RAB9AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | FAAH 1/4885CES2 62/4885TGFBR1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.